A randomized double-blind, placebo-controlled, parallel-group, fixed single-dose regimen (SR141716 [rimonabant] 20 mg), multicenter study to assess the efficacy and safety of SR141716 in obese patients with dyslipidemia.
Phase of Trial: Phase III
Latest Information Update: 21 Jul 2009
At a glance
- Drugs Rimonabant (Primary)
- Indications Dyslipidaemias; Obesity
- Focus Registrational; Therapeutic Use
- Acronyms VENUS
- Sponsors Sanofi
- 21 Jul 2009 Actual patient number (915) added as reported by ClinicalTrials.gov.
- 05 Nov 2008 Sanofi-aventis have reported in a media release that development of rimonabant has been discontinued.
- 05 Nov 2008 Status changed from active, no longer recruiting to discontinued., as reported by sanofi-aventis.